22
study gliding motility and potential antiplasmodial drug candidates. 
29
The malaria parasite Plasmodium falciparum is able to synthesize heme de novo suggesting it 30 is a potential target pathway for new antimalarial drugs (12). P. falciparum uses two forms of 31 ALAD for heme biosynthesis: One is host-derived ALAD (HsALAD) imported from infected 32 erythrocytes (1) and the second is an endogenous form (PfALAD) (10) targeted to the 33 apicoplast (2) . PfALAD accounts for ~10% of total parasite-derived ALAD activity but may 34 be indispensible during certain life-cycle stages or for apicoplast homeostasis (2). In contrast 35 to HsALAD, PfALAD possesses a binding site for allosteric Mg 2+ (10) similar to the
36
Wolbachia protein, for which a functional competition with the activation by Mg 2+ is part of 37 the inhibitory mechanism (4). We therefore reasoned that wALADins might be effective 38 inhibitors of PfALAD and hence possess antimalarial activity.
39
To determine the antiplasmodial activity of wALADins, P. falciparum strain 3D7 parasites
40
were cultivated in human A+ erythrocytes under a defined gaseous atmosphere (92% CO 2 ,
41
3% O 2 , 5% CO 2 ) at 37 °C as published (8). Parasitemia was adjusted to 0.2 -0.5% before 42 parasites were exposed to 62.5 µM wALADin1 (Fig. 1A, Table 1) , the derivatives or 0.625%
43
DMSO for 72 h. Compound 1 (wALADin1) and derivatives 4 and 7 reduced parasitemia to wALADin-benzimidazoles is shown in Figure 1H and provided by Dr. V. Arun Nagaraj). Enzymatic assays were performed as described previously 62 for orthologs using 250 nM PfALAD in 100 mM Tris-HCl pH 8.0, 1 mM MgCl 2 , 200 µM 5-
63
ALA for 60 min (4). wALADin1 and 9 showed marginal inhibitory activity at the highest 64 concentration tested (533 µM), whereas neither 4 nor 7 were inhibitory ( Table 1) . Although it 65 may not be ruled out that under physiological conditions the PfALAD may be more 66 susceptible to inhibition, it is likely that the antiplasmodial activity elicited in the one-digit (4) 67 or low two-digit µM range (wALADin1, 7) is mediated via an alternative target than ALAD. by >10-fold (6).
83
To delineate the activity of wALADins against other malarial parasite life-cycle stages
84
(sporozoites and liver stages) we used the rodent parasite P. berghei ANKA. To assess gliding 85 motility 10,000 infective sporozoites were pre-incubated with compounds for 15 min on ice.
86
After 30 min of gliding on BSA-coated glass slides, samples were fixed and gliders and non- also prevented sporozoite adhesion at 40 µM, but showed no effect on gliding motility at 94 lower concentrations (Fig. 2A) . Control compounds 2 and 3 had no effect on sporozoite 95 motility. As gliding motility is required for successful invasion of hepatocytes, we tested 96 whether 7 was able to inhibit this important infection process. Sporozoites were pre-incubated 97 with 7 as described above and allowed to invade immortalized human hepatoma cells (Huh7)
98
for 90 min before samples were fixed and stained according to the two-color host-cell 99 invasion method (9). 7 blocked sporozoite invasion into hepatoma cells (Fig. 2 B) , 100 presumably as a result of suppressed gliding motility. In contrast to invasion into hepatocytes,
101
intrahepatocytic replication was not affected by wALADins at concentrations up to 40 µM
102
( Fig. 2 C-D) . AlamarBlue® cytotoxicity assays at 40 µM of compound revealed a moderate
103
antiproliferative effect of wALADin1 against Huh7 cells, but not of 4 or 7, confirming 104 specificity of the latter compounds. Due to its potent effect on sporozoite gliding motility, we 105 named 7 "wALADin-derived inhibitor of Plasmodium motility and invasion1 (ALPin1)"
106
(chemical structure in Fig. 2 E) . As a small molecule tool ALPin1 may help identify unknown 107 components of the actin-myosin motor-dependent gliding machinery (3, 7).
108
In addition to the specificity of the biological effect, the drug-like chemical properties of 109 wALADin-benzimidazoles, easy synthetic accessibility, and steep antiplasmodial activity 110 profile (Fig. 1H) 
